To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Domainex Collaborates with St George’s University and The University of Manchester for Asthma Treatment
Read time: 1 minute
Domainex Ltd
,
St George’s University of London
, and
The University of Manchester
Domainex will provide lead optimization services for an asthma research programme being undertaken at St George’s. The total contract value for Domainex exceeds £1.5 million in research fees over two years.
Scientists led by Clive Robinson, Professor in Respiratory Cell Science at St George’s, working in collaboration with Professor David Garrod at Manchester and a team from Domainex, have discovered drug-like compounds that inhibit Der p1, an enzyme that triggers asthma attacks. St George’s University of London and The University of Manchester have recently been awarded a £4 million research grant from the Wellcome Trust's Seeding Drug Discovery Initiative to take this research programme forward.
Domainex will apply its LeadBuilder technology - which uses virtual screening capability to select chemical compounds suitable for rapid progression - and its medicinal chemistry expertise to assist the St George’s team to develop a drug candidate to take into clinical trials.
Eddy Littler, Chief Executive Officer of Domainex, said: “This collaboration with St George’s University of London and The University of Manchester demonstrates Domainex’s core expertise in computational and medicinal chemistry. It is also a testament to our commitment to the support of translational research in academia. The combination of LeadBuilder and our medicinal chemistry expertise creates a powerful drug discovery tool.”
Professor Clive Robinson said: “The innovative services provided by Domainex’s scientists, together with the support of the Wellcome Trust, will help us to accelerate the development of our exciting anti-asthma compounds.”
Professor David Garrod said: “This is a most exciting development in a productive on-going collaboration that promises to bring real benefit to the millions who suffer from respiratory allergies.”
have announced that they are collaborating on a new drug discovery programme to provide a better treatment for asthma.
Domainex will provide lead optimization services for an asthma research programme being undertaken at St George’s. The total contract value for Domainex exceeds £1.5 million in research fees over two years.
Scientists led by Clive Robinson, Professor in Respiratory Cell Science at St George’s, working in collaboration with Professor David Garrod at Manchester and a team from Domainex, have discovered drug-like compounds that inhibit Der p1, an enzyme that triggers asthma attacks. St George’s University of London and The University of Manchester have recently been awarded a £4 million research grant from the Wellcome Trust's Seeding Drug Discovery Initiative to take this research programme forward.
Domainex will apply its LeadBuilder technology - which uses virtual screening capability to select chemical compounds suitable for rapid progression - and its medicinal chemistry expertise to assist the St George’s team to develop a drug candidate to take into clinical trials.
Eddy Littler, Chief Executive Officer of Domainex, said: “This collaboration with St George’s University of London and The University of Manchester demonstrates Domainex’s core expertise in computational and medicinal chemistry. It is also a testament to our commitment to the support of translational research in academia. The combination of LeadBuilder and our medicinal chemistry expertise creates a powerful drug discovery tool.”
Professor Clive Robinson said: “The innovative services provided by Domainex’s scientists, together with the support of the Wellcome Trust, will help us to accelerate the development of our exciting anti-asthma compounds.”
Professor David Garrod said: “This is a most exciting development in a productive on-going collaboration that promises to bring real benefit to the millions who suffer from respiratory allergies.”
